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Abstract Current toxicity protocols relate measures of
systemic exposure (i.e. AUC, Cmax) as obtained by non-
compartmental analysis to observed toxicity. A complicat-
ing factor in this practice is the potential bias in the esti-
mates defining safe drug exposure. Moreover, it prevents
the assessment of variability. The objective of the current
investigation was therefore (a) to demonstrate the feasibility
of applying nonlinear mixed effects modelling for the
evaluation of toxicokinetics and (b) to assess the bias and
accuracy in summary measures of systemic exposure for
each method. Here, simulation scenarios were evaluated,
which mimic toxicology protocols in rodents. To ensure
differences in pharmacokinetic properties are accounted
for, hypothetical drugs with varying disposition properties
were considered. Data analysis was performed using non-
compartmental methods and nonlinear mixed effects mod-
elling. Exposure levels were expressed as area under the
concentration versus time curve (AUC), peak concentra-
tions (Cmax) and time above a predefined threshold (TAT).
Results were then compared with the reference values to
assess the bias and precision of parameter estimates. Higher
accuracy and precision were observed for model-based
estimates (i.e. AUC, Cmax and TAT), irrespective of group
or treatment duration, as compared with non-compartmen-
tal analysis. Despite the focus of guidelines on establishing
safety thresholds for the evaluation of new molecules in
humans, current methods neglect uncertainty, lack of pre-
cision and bias in parameter estimates. The use of nonlinear
mixed effects modelling for the analysis of toxicokinetics
provides insight into variability and should be considered
for predicting safe exposure in humans.
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Abbreviations
AUC Area under the concentration versus time curve
Cmax Peak concentrations
ICH International conference on harmonisation of
technical requirements for registration of
pharmaceuticals for human use
PD Pharmacodynamics
PK Pharmacokinetics
TAT Time above a concentration threshold
Introduction
The purpose of toxicokinetic studies in the evaluation of
safety pharmacology and toxicity is the prediction of the
risk that exposure to a new chemical or biological entity
represents to humans [1, 2]. Understanding of the rela-
tionships between drug exposure, target engagement (i.e.,
activation or inhibition) and downstream biological effects
of a given physiological pathway can provide insight into
the mechanisms underlying both expected and ‘unexpect-
ed’ toxicity [3] (Fig. 1). In addition, the use of a
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mechanism-based approach has allowed better interpreta-
tion of time-dependencies in drug effect, which are often
observed following chronic exposure to a drug (e.g., de-
layed toxicity) [4, 5].
Despite the increased attention to the importance of
toxicokinetics in drug discovery and during the early stages
of clinical development, the extrapolation and prediction of
a safe exposure range in humans from preclinical ex-
periments continues to be one of the major challenges in
R&D (Fig. 2) [6]. Irrespective of the choice of ex-
perimental protocol, a common practice in toxicology re-
mains the assessment of empirical safety thresholds, in
particular the no observed adverse effect level (NOAEL),
which is a qualitative indicator of acceptable risk. Even
though support for the existence of thresholds has been
argued on biological grounds [7–9], the NOAEL has been
used to establish the safe exposure levels in humans. In
fact, this threshold represents a proxy for another threshold,
i.e., the underlying no adverse event level (NAEL).
The definition of the NOAEL varies from source to
source [6]. Its calculation involves the determination of the
lowest observed adverse effect level (LOAEL), which is
the lowest observed dose level for which AEs are recorded.
The NOAEL is the dose level below this. If no LOAEL is
found, then the NOAEL cannot be determined. Usually, in
the assessment of the LOAEL measures of systemic ex-
posure are derived, such as area under the concentration
versus time curve (AUC) and peak concentrations (Cmax),
which serve as basis for the maximum allowed exposure in
dose escalation studies in humans [10]. The aforemen-
tioned practices in safety and toxicity evaluation are driven
by regulatory guidance [11, 12]. The scope of these guid-
ances is to ensure that data on the systemic exposure
achieved in animals is assessed in conjunction with dose
level and its relationship to the time course of the toxicity
or adverse events (Fig. 2). Another important objective is
to establish the relevance of these findings for clinical
safety as well as to provide information aimed at the op-
timisation of subsequent non-clinical toxicology studies.
Whilst the scope and intent of such guidance are well
described since 1994, when it was introduced by the ICH,
there has been much less attention to requirements for the
analysis and interpretation of the data. In fact, precise de-
tails on the design of toxicokinetic studies or the statistical
methods for calculating or estimating the endpoints or
variables of interest, are not specified [13–15]. Instead, the
assessment of exposure often takes places in satellite
groups, which may not necessarily present the (same) ad-
verse events or toxicity observed in the main experimental
group. This is because of interferences associated with
blood sampling procedures, which may affect toxicological
findings. For this same reason, blood sampling for phar-
macokinetics is often sparse [16]. Such practice also di-
verges from efforts in models in environmental toxicology,
a field in which deterministic, physiologically-based
pharmacokinetic models have been used for a long time
[17, 18].
As a consequence, safety thresholds are primarily
derived from inferences about the putative pharmacoki-
netic profiles in the actual treatment group. Furthermore,
these thresholds rely on the accuracy of composite profiles
obtained from limited sampling in individual animals.
Composite profiles consist of pooled concentration data,
which is averaged per time point under the assumption that
inter-individual differences are simply residual variability,
rather than intrinsic differences in pharmacokinetic
Fig. 1 Diagram displaying the
contribution of toxicokinetics
and pharmacology for the
characterisation of target-related
adverse events and safety risk
assessment. The circle depicting
target efficacy highlights the
role of information regarding
the primary target engagement
for safety risk assessment. Data
on the target efficacy is usually
obtained during in vitro and
in vivo screening. The arrow
indicates that inferences can be
made about safety and risk
based on the evidence from drug
exposure and organ-specific
toxicity data. Reprinted with
permission from Horii 1998 [3]
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processes [19]. Pharmacokinetic parameters such as area-
under-concentration-time (AUC) and observed peak con-
centrations (Cmax) can then be either derived from the
composite profile or by averaging individual estimates
from serial profiles in satellite animals when frequent
sampling schemes are feasible. Given that the parameters
of interest are expressed as point estimates, within- and
between-subject variability as well as uncertainty in esti-
mation are not accounted for. In addition, pharmacokinetic
data generated from different experiments are not
evaluated in an integrated manner, whereby drug disposi-
tion (e.g., clearance) can be described mechanistically or at
least compartmentally in terms of both first and zero order
processes. This is further complicated by another major
limitation in the way exposure is described by naı¨ve
pooling approaches, i.e., the impossibility to accurately
derive parameters such as cumulative exposure, which may
be physiologically a more relevant parameter for late onset
or cumulative effects (e.g. lead toxicity, aminoglycosides)
[20, 21]. Time spent above a threshold concentration may
also bear greater physiological relevance for drugs which
cause disruption of homeostatic feedback mechanisms.
Such parameters cannot be described by empirical ap-
proaches due to limitations in sampling frequency.
By contrast, population pharmacokinetic-pharmacody-
namic methodologies have the potential to overcome most
of the aforementioned problems. Whilst the application of
modelling in the evaluation of efficacy is widespread and
well-established across different therapeutic areas [22–24],
current practices have undoubtedly hampered the devel-
opment of similar approaches for the evaluation of adverse
events, safety pharmacology and toxicity. It should be
noted that in addition to the integration of knowledge from
a biological and pharmacological perspective, population
models provide the basis for the characterisation of dif-
ferent sources of variability, allowing the identification of
between-subject and between-occasion variability in pa-
rameters [25]. These random effects do not only reflect the
evidence of statistical distributions. They can be used for
inference about the mechanisms underlying adverse events
and toxicity. In fact, recent advancements in environmental
toxicology have shown the advantages of PBPK/PD mod-
elling as a tool for quantifying target organ concentrations
and dynamic response to arsenic in preclinical species [26].
The aim of this investigation was therefore to assess the
relative performance of model-based approaches as com-
pared to empirical methods currently used to analyse
toxicokinetic data. We show that, modelling is an iterative
process which allows further insight into relevant biologi-
cal processes as well as into data gaps, providing the basis
for experimental protocol optimisation. We illustrate the
concepts by exploring a variety of scenarios in which
Fig. 2 General toxicity data
generated to support early
clinical trials is gathered in the
pre-IND/CTX stage. After IND/
CTX submission, the regulatory
agency will confirm whether
adequate evidence of safety has
been generated for human trials.
Parameters derived from
toxicokinetic data, such as the
NOAEL, play a key role in the
approval of protocols for first-
time-in human studies. IND/
CTX investigational new drug
application, NDA new drug
application, TK toxicokinetic
study. Reprinted with
permission from Horii 1998 [3]
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hypothetical drugs with different disposition properties are
evaluated.
Methods
Using historical reference data from a range of non-s-
teroidal anti-inflammatory compounds for which phar-
macokinetic parameter estimates were known in rodents,
a model-based approach was used to simulate the out-
comes of a 3-month study protocol, in which toxicoki-
netic data for three hypothetical drugs were evaluated.
The selection of non-steroidal anti-inflammatory com-
pounds as paradigm for this analysis is due to the
mechanisms underlying both short and long term adverse
events as well as the evidence for a correlation between
drug levels and incidence of such events in humans. In
fact, a relationship has been identified between the degree
of inhibition of cyclooxygenase at the maximum plasma
concentration (Cmax) of individual non-steroidal anti-in-
flammatory drugs and relative risk (RR) of upper gas-
trointestinal bleeding/perforation [27].
Simulation of drug profiles using predefined
pharmacokinetic models
The impact of differences in drug disposition on bias and
precision of the typical measures of systemic exposure was
explored by including three different scenarios based on a
one-compartment pharmacokinetics with linear and non-
linear (Michaelis–Menten) elimination as well as a two-
compartment pharmacokinetics. Parameter values for each
scenario are shown in Table 1. In all simulation scenarios,
residual variability was set to 15 %. For the purposes of
this exercise, we have assumed that the models used as
reference show no misspecification. In addition, we have
considered the use of a homogeneous population of ro-
dents, avoiding the need to explore covariate relationships
in any of the models.
Experimental design
Experimental procedures were defined according to current
guidelines for the assessment of toxicity. A summary of the
sampling schemes and experimental conditions is shown in
Fig. 3 Overview of a simulated
dataset along with the predicted
pharmacokinetic profiles for
each of the experimental
scenarios, in which blood
samples are collected from 3
animals per sampling time
point. Dots represent simulated
concentrations at the pre-
defined sampling times, whereas
the solid black line depicts the
population predicted profile
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Table 2. The protocol design for each experiment with the
three hypothetical drugs was based on protocols typically
used for chronic toxicity evaluation. Four treatment groups
receiving oral daily doses of vehicle, 10, 30, and 100 mg/
kg/day were tested throughout this set of virtual ex-
periments. The same treatment groups were present in all
duration cohorts (1 week, 1 month or 3 months). Satellite
groups each were used to characterise the pharmacokinet-
ics under the dosing conditions in the animals used for the
assessment of toxicity. This procedure ensures the avail-
ability of more frequent blood samples for toxicokinetics,
while not influencing the assessment of the toxicity. Two
different sampling schedules were investigated, namely,
composite sampling and serial sampling. For the sake of
comparison, the same number of samples was collected in
both cases. For composite sampling, blood was collected
from three animals in the satellite group at predetermined
sampling time points, namely, 0.1, 0.4, 1, 1.5, 4, 8, 24 h
after drug administration on sampling days (see Table 2).
The allocation of animals to each sampling time point was
random within the constraint that all animals were sampled
an equal number of times. An overview of a simulated
dataset along with the predicted pharmacokinetic profiles
for each of the experimental scenarios is shown in Fig. 3.
Derivation of true exposure levels
Five different measures of exposure were derived from the
simulated concentration profiles obtained from the models
used for simulation. They included the 24-h area under the
concentration versus time curve (AUC), the maximum
concentration (Cmax), the time above a threshold drug con-
centration (TAT), the predicted 6-month cumulative AUC
and the predicted 6-month Cmax. These exposure measures
can be seen alongside the formula used for their calculation
in Table 3. The threshold for adverse events was assumed to
be 10 lg/ml. This arbitrary value was selected for illustra-
tive purposes only. The simulations (n = 200 replicates)
were performed assuming repeat dosing for up to 6 months
(3 months beyond the treatment duration presented the in-
vestigated studies) in order to evaluate the implications of
longer periods of drug exposure.
Calculation of measures of exposure by non-
compartmental analysis
Data from composite sampling across all satellite animals
were used to determine the overall drug exposure, which
consisted in averaging the simulated concentrations at each
sampling time point. A similar approach was used for serial
sampling, but in this case, drug exposure was calculated for
each individual animal and then averaged over the cohort.
In both cases, the arithmetic mean and geometric mean
were used as summary statistics. As non-compartmental
methods do not allow extrapolation beyond the actual ex-
perimental conditions, only three of the five measures of
exposure were derived, namely, the AUC, estimated using
Table 1 Pharmacokinetic models used to assess the impact of
varying disposition properties on the estimation of safety thresholds
Model A: One-compartment model (1 CMT)
Parameter Pop estimate BSV (%)
KA (h-1) 13.46 50
V (ml/kg) 49.4 16
CL (ml/h) 2.72 20
Model B: One compartment model with Michaelis–Menten
elimination (1 CMT ? MM). Parameter values were chosen to ensure
departure from dose proportionality at the highest dose
Parameter Pop estimate BSV (%)
Vmax (mg/h) 2.72 20
Km (mg/ml) 1 –
Ka (h-1) 13.46 50
V (ml/kg) 49.4 16
Model C: Two-compartment model (2 CMT). The values for the
absorption and elimination rate constants were selected in such a way
that slow accumulation of drug is observed at stead-state conditions
after daily dosing for approximately 2 weeks
Parameter Value Variability (%)
Ka (h-1) 0.55 50
V (ml/kg) 49.4 16
CL (ml/h) 2.72 20
K12 (h-1) 0.3 –
K21 (h-1) 0.05 32
Table 2 Experimental design
characteristics of treatment and
satellite groups in a general
toxicity study with serial and
composite pharmacokinetic
sampling
Duration Numbers of animals Sampling scheme
1 week Toxicity: 4 per dose group
Satellite: 3 per dose group
Toxicity: Composite 2 per animal
Satellite: Serial profiles from day 1 only
1 month Toxicity: 10 per dose group
Satellite: 3 per dose group
Toxicity: Composite 2 per animal
Satellite: Serial profiles from day 1 and 28
3 months Toxicity: 12 per dose group
Satellite: 3 per dose group
Toxicity: Composite: week 4, week 13
Satellite: Serial profiles from day 1, week 4, week 13
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the linear-logarithmic trapezoidal rule, the Cmax, and the
TAT.
Calculation of measures of exposure by nonlinear
mixed effects modelling
For each simulation replicate, drug concentration profiles
were fitted to pharmacokinetic models using the first-order
conditional estimation method with interaction (FOCEI), as
implemented in NONMEM. Model building steps were
limited to the same structural models used for the initial
simulations under the assumption that pharmacokinetic
properties of the drugs are known at the time toxicology
experiments are performed. Model convergence was de-
termined by successful minimisation and estimation of the
covariance step. Data below the lower quantification limit
(BQL) were omitted to mimic experimental conditions in
which imputation methods are not applied. Estimates for
all five measures of exposure were calculated by using
same procedures applied for the reference values obtained
during the initial simulation step (see Table 3).
Comparison
To ensure accurate estimates of bias and precision of the two
methodologies, the process of simulation and estimation of
exposure (using non-compartmental vs. nonlinear mixed ef-
fects)was repeated 200 times. Bias and precisionwere assessed
by the relative error, scaled relativemean error (SRME) and the

















All simulations and fitting procedures described above
were performed in NONMEM 7.1 [29]. Data manipulation
and statistical and graphical summaries were performed in
R 3.0.0 [30].
Results
The use of simulated data for the evaluation of hypothetical
scenarios provided clear insight of the impact of current
practices on the accuracy and precision of safety thresh-
olds, and in particular of the NOAEL. Irrespective of the
use of serial or sparse sampling schemes for the charac-
terisation of the concentration versus time profiles, model
convergence rates were usually high, with successful
completion of the covariance step. An overview of the
convergence rates is presented in Table 4.
To facilitate the comparison of the magnitude of bias
and precision, results from modelling are shown together
with the parameter values obtained from non-compart-
mental analysis where applicable. Due to the large number
of experimental conditions to be summarised, here we
present a brief description of the relative errors obtained in
the 3-month protocol, for AUC, Cmax and TAT. All other
experimental conditions, including an overview of the
scaled relative mean error (SRME) and the coefficient of
variation (CV) are presented in tabular format as supple-
mental material (Table S1).
In Fig. 4, the relative errors are presented for the esti-
mates for AUC, Cmax and TAT. The relative errors were
Table 3 Exposure measures derived from the simulated concentra-
tion vs. time profiles. The assessment of bias and precision in the
estimates of safety thresholds was based on these secondary
pharmacokinetic parameters, which are shown alongside the formula
used for their calculation. Individual predicted drug concentrations
are denoted by Cp(t)






24-h Cmax Cmax24 max Cp sð Þ : t  24\s\t
  










Predicted 6-month Cmax Cmax24 max Cp sð Þ : 0\s\6months
  
Table 4 Rates of convergence and covariance (parameter precision)
estimation based on nonlinear mixed effects modelling. Simulated
drug concentrations collected at the predefined sampling times were





1 CMT 99.75 99.75
1 CMT ? MM 99.75 99.75
2 CMT 100 100
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clearly smaller when measures of exposure were derived
by modelling, as compared to the results obtained by non-
compartmental analysis. In fact, the accuracy and precision
of model-based estimates for all three measures of expo-
sure were similar across the different dosing groups and
treatment durations. Non-compartmental estimates of
exposure showed significantly higher bias and less preci-
sion in all scenarios. The performance for model-based
exposure estimates derived from the 3-month protocol is
summarised in Fig. 5.
Our results also reveal the impact of composite versus
serial sampling on bias and precision. For both model-
based and non-compartmental methods, the coefficient of
variation increased with composite designs (with 8 ani-
mals), as compared to serial sampling designs (with 3
animals). However, the increase in precision for non-
compartmental method was larger than for model-based
estimates. It should also be noted that Cmax was consis-
tently over-estimated by the non-compartmental method.
We also demonstrate that the use of arithmetic and
geometric means for NCA had minor impact in these
relatively small groups.
Lastly, it was found that that nonlinearity in pharma-
cokinetics also has an important effect on bias and preci-
sion when sparse samples and limited number of dose
levels are evaluated experimentally. Model-based estimates
in the 1 CMT ? MM scenario showed increased bias
compared to the 1 CMT and 2 CMT scenarios.
Discussion
In this investigation we have attempted to identify impor-
tant limitations in the use of non-compartmental methods
for the analysis of toxicokinetic data. Irrespective of the
limited number of scenarios, our findings illustrate the
feasibility of using hierarchical models for the evaluation
of toxicokinetic data using a well-established pa-
rameterisation for drug disposition processes. Furthermore,
given that model performance in the analysis of toxicoki-
netic data has been previously evaluated [31], we have
been able to focus on the performance of measures of ex-
posure that cannot be derived from empirical approaches,
i.e., non-compartmental methods [32].
It is important to highlight that the use of compartmental
models, instead of physiologically-based pharmacokinetic
models in this exercise was required to avoid issues such as
parameter identifiability [33], which would arise from the
bFig. 4 Relative errors of parameter estimates for AUC (upper panel),
Cmax (mid panel) and TAT (lower panel). Data refers only to the
3-month toxicology protocol design following administration of
30 mg/kg/day of three hypothetical drugs with different pharmacoki-
netic profiles. Similar results were found for other cohorts in which 10
and 100 mg/kg/day were evaluated. Dots represent the median, boxes
show the 25th and 75th percentiles, error bars denote the 5th and 95th
percentiles. The red line shows the reference level for relative error
equal to zero. Composite composite sampling, GEOMEAN geometric
mean, MEAN arithmetic mean, MODEL nonlinear mixed effects
modelling, NCA non-compartmental analysis and Serial serial
sampling (Color figure online)
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data generated in standard toxicology protocols. The
plasma pharmacokinetic profiles derived for the hypo-
thetical compounds were considered realistic enough to
reflect the time course of drug levels observed in many
toxicology studies. In fact, these profiles are greatly af-
fected by the standard sampling schemes in toxicology
experiments, which may not allow one to identify more
than one- and two-compartment models. Moreover, con-
sideration was given to the implications that high doses
may have on drug metabolism and elimination. A phar-
macokinetic model with Michaelis–Menten elimination
was also included to ensure accurate characterisation of
dose- and concentration-dependent pharmacokinetics,
which is likely to occur for many compounds at least in one
experimental dose level. Saturation of metabolism has
implications for the interpretation of safety thresholds,
especially if nonlinearity is not observed at pharmaco-
logically relevant levels. The results presented here should
therefore be indicative of the most common toxicokinetic
profiles. Given the evidence of the superiority of nonlinear
mixed effects modelling to describe sparse pharmacoki-
netic data [34–37], we anticipate the possibility to gener-
alise the lessons learned to a much wider range of drugs,
for which pharmacokinetic parameter values may differ
considerably from those presented here.
Parameter precision and bias
As shown in Table 4, the high convergence rates of models
and high success rate for the computation of the covariance
matrix for the scenarios tested here confirm the robustness
of results obtained using nonlinear mixed-effects mod-
elling. Despite variations in bias and precision, parameter
precision was consistently high. Whilst these results must
be interpreted under the assumption of minor or no model
misspecification, the use of modelling showed particularly
good performance (CV\ 10 % and SRME\ 10 % for
within study exposure predictions and SRME\ 15 % for
long term exposure predictions). Such high levels of pre-
cision may not be required for safe exposure evaluation
where between-subject variability in humans is expected to
be larger and comparatively large uncertainty factors are
routinely used. This suggests that a model-based approach
will enable considerable reductions in the numbers of
animals and/or samples to be used in experimental proto-
cols whilst providing acceptable parameter precision.
Moreover since optimal design methodologies for model-
based analysis are well established, further refinement of
the experimental protocol design is feasible if experimen-
talists and statisticians choose nonlinear mixed effects
modelling as the primary method of analysis.
On the other hand, the presence of bias in some of the
experimental conditions presented here has clear implica-
tions for the so-called safety margin and toxicological
cover to be used as proxy for risk during clinical devel-
opment, especially for Cmax, which is consistently over-
estimated. This is due to the definition of peak concentra-
tions in non-compartmental analysis where CM is neces-
sarily greater than or equal to Cp t ¼ Tmaxð Þ, where Tmax
represents the time point which maximises the true con-
centration–time profile. When the sampling scheme con-
tains other observations in the region of Tmax there is
potential for neighbouring sampling times to produce
higher than predicted concentrations due to natural vari-
ability. This is a fundamental limitation in the methodology
in that more samples around Tmax which intuitively should
increase confidence, actually leads to more bias. In other
words, with non-compartmental analysis precisely esti-
mating Tmax comes at the unavoidable cost of biased es-
timation of Cmax. Model-based analysis has an additional
advantage in this respect. Without model misspecification
issues, maximum likelihood estimates are (asymptotically)
unbiased and have the property that increased sampling
uniformly increases precision. The implications of model
specification issues are discussed further in the limitations
section. Given that the residual variability in the scenarios
Fig. 5 Overview of the relative errors of model-based estimators of
long-term exposure, i.e. predicted peak concentrations after 6 months
(6 mth Cmax) and cumulative area under the concentration vs. time
curve (6 mth cum. AUC). The analysis is based on the data from a
3-month toxicology protocol following administration of 30 mg/
kg/day of three hypothetical drugs with different pharmacokinetic
profiles. Similar results were found for other cohorts in which 10 and
100 mg/kg/day were evaluated. Dots represent the median, boxes
show the 25th and 75th percentiles, error bars denote 1.5 times the
interquartile range from the median. The red line shows the reference
level for relative error equal to zero (Color figure online)
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was not large (i.e., fixed at 15 %), the bias seen here may
increase with larger residual noise, which may occur in real
life. The issue of bias can be further mitigated by the ap-
propriate use of predictive checks. An example of the
procedures can be found in the supplemental material for
naproxen [38], where predictive checks including data
analysed by non-compartmental methods illustrate how to
assess bias in AUC and Cmax.
Data integration
In contrast to non-compartmental methods, our investiga-
tion was based on an integrated analysis of the data, i.e. by
combining the results from all experimental cohorts. This is
undoubtedly the primary driver of the increased accuracy
and precision in model-based estimates [38–40]. In fact, we
envisage further improvement by incorporating pharma-
cokinetic data from other experiments in the same species,
which are normally collected during the preclinical
evaluation of a molecule, as for instance during the char-
acterisation of drug metabolism. Such an increase in pre-
cision would represent further adherence to the reduction,
refinement and replacement principle (3 Rs) in ethical
animal studies [41, 42]. It should also be noted that the
possibility of data integration provides the basis for com-
bining safety pharmacology and adverse event data, en-
abling the development of toxicokinetic-toxicodynamic
models and consequently allowing for the evaluation of
exposure–response relationships in a continuous manner.
Such models would represent an advancement in toxicol-
ogy and risk management and mitigation, as they provide
the basis for mechanism-based inferences about unwanted
effects, irrespective of their incidence or occurrence in the
actual experimental protocol [4, 43].
It is important to realise that the typical point estimates
of parameters derived from empirical methods to describe
drug exposure give an undue measure of certainty, allow-
ing for the propagation of uncertainty from estimation to
uncertainty in safety thresholds, such as NOAEL. Whilst
there exist methods for estimating uncertainty in a com-
posite or destructive sampling approach [44–46], their
adoption in experimental research has not been widespread
due in part to the requirement of normality assumptions on
toxicokinetic parameters, and an acceptance in guidelines
towards possibly large amounts of imprecision [12].
As demonstrated here, model-based methods allow
simulations to be performed in conjunction with estimation
procedures, enabling the assessment of uncertainty asso-
ciated with a variety of causes such as uninformative study
design, large variability and/or unknown covariates. This
entails an increase in the quality of the decision-making
process and ultimately in the interpretation of the estimated
safety thresholds [47].
Given the success of modelling and simulation in drug
development [48–50], one should ask why the field of
toxicology has yet to embrace it. The scepticism regarding
the value of model-based approaches often arises from a
view that knowledge about the model is required in ad-
vance [51, 52]. This argumentation is however flawed.
Non-linear mixed effects modelling is specifically intended
to efficiently process sparse data. The performance of the
model-based exposure estimates in the composite designs
is illustrative of this. Moreover, the inference principles
used for hypothesis generation and characterisation of drug
disposition parameters relies on the use of statistical cri-
teria that are sophisticated enough to allow model identi-
fication and its suitability for subsequent parameter
estimation purposes. Moreover, it should be noted that non-
compartmental methods also make implicit assumptions
about the underlying concentration versus time profile. For
instance, with a linear-logarithmic analysis of AUC, first-
order elimination kinetics is assumed. The suitability of
measures of central tendency will also depend on the as-
sumed distribution characteristics and on residual vari-
ability. These assumptions are often implicit and their
validity regarding the dataset at hand cannot be checked
during the analysis. There are no strong statistical justifi-
cation to support the choice for non-compartmental meth-
ods, other than the lack of technical knowledge and
familiarity with hierarchical modelling by toxicologists in
industry and regulatory agencies. The persistence in the use
of non-compartmental methods bears an unnoticed cost,
i.e., the ethical cost of utilising more animals than what is
really necessary.
Potential limitations
In the present investigation, the impact of model mis-
specification in the analysis of general toxicity data was not
investigated. For exposure measures which have a corre-
sponding estimate based on non-compartmental methods
(e.g. AUC and Cmax), the impact is likely to be small as
long as the model fit to the data is good. This is because
these measures are highly dependent on the observations.
Therefore, accurate prediction of the observed profiles
during model evaluation is likely to result in accurate
prediction of these exposure variables. Model misspecifi-
cation however, may lead to significant bias when exposure
predictions are made outside the experimental context (i.e.
longer timescales or different dosing regimens) [53, 54].
This is a risk when the pharmacokinetics of the drug is
nonlinear or shows metabolic saturation. To mitigate such
effects we recommend that model selection criteria take
into account not only the ability to describe data, but also
the physiological relevance of model assumptions. When
model development ends in multiple competing models
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performing similarly with respect to statistical selection
criteria, clear reporting of such model uncertainty is nec-
essary. Model averaging should be discouraged when
predictions arising from different model differ significantly
[55]. Finally, parameter uncertainty should be incorporated
into the predictions of exposure to ensure accurate
evaluation of risk and potential therapeutic window of the
compound.
In summary, evaluation of safety is paramount for the
progression of new molecules into humans. Historically,
toxicology experiments have evolved based the assumption
that experimental findings suffice to demonstrate the ab-
sence or presence of risk. This assumption disregards
growing evidence of the advantages of data integration for
the characterisation of drug properties. Whilst the chal-
lenges R&D faces to translate toxicity findings from ani-
mals to humans may remain, the use of an integrated
approach to the analysis and interpretation of toxicokinetic
data represents further adherence to the 3Rs principle,
enabling significant reduction in number of animals re-
quired for the evaluation of toxicokinetics.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
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